Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Animals (1)
- CD4-Positive T-Lymphocytes (1)
- Cell Differentiation (1)
- Cell Survival (1)
- Cells, Cultured (1)
-
- Central Nervous System (1)
- Cerebellum (1)
- Cytokines (1)
- Disease Models, Animal (1)
- Disease Progression (1)
- Encephalomyelitis, Autoimmune, Experimental (1)
- Female (1)
- Guanabenz (1)
- Guanabenz--pharmacology (1)
- Inflammation (1)
- Interferon-gamma (1)
- Mice (1)
- Mice, Inbred C57BL (1)
- Multiple Sclerosis (1)
- Multiple Sclerosis--drug therapy (1)
- Myelin Sheath (1)
- Oligodendroglia (1)
- Oligodendroglia--cytology (1)
- Rats (1)
- Rats, Sprague-Dawley (1)
- Stem Cells (1)
Articles 1 - 2 of 2
Full-Text Articles in Pharmaceutical Preparations
Unmasking Of Myoclonus By Lacosamide In Generalized Epilepsy, Daniel Birnbaum, Mohamad Z. Koubeissi
Unmasking Of Myoclonus By Lacosamide In Generalized Epilepsy, Daniel Birnbaum, Mohamad Z. Koubeissi
Neurology Faculty Publications
Lacosamide is a new-generation antiseizure medication that is approved for use as an adjunctive treatment and monotherapy in focal epilepsy. Its use in generalized epilepsy, however, has not been adequately evaluated in controlled trials. We report a 67-year-old woman who experienced new-onset myoclonic seizures after initiation of lacosamide. We presume that she had an undiagnosed generalized epilepsy syndrome, likely juvenile myoclonic epilepsy. Myoclonic seizures were not reported before introducing lacosamide and completely resolved after lacosamide was discontinued. This suggests that lacosamide may have the potential to worsen myoclonus, similar to what has been reported with another sodium channel agent, lamotrigine, …
Pharmaceutical Integrated Stress Response Enhancement Protects Oligodendrocytes And Provides A Potential Multiple Sclerosis Therapeutic., Sharon W Way, Joseph R Podojil, Benjamin L Clayton, Anita Zaremba, Tassie L Collins, Rejani B Kunjamma, Andrew P Robinson, Pedro Brugarolas, Robert H. Miller, Stephen D Miller, Brian Popko
Pharmaceutical Integrated Stress Response Enhancement Protects Oligodendrocytes And Provides A Potential Multiple Sclerosis Therapeutic., Sharon W Way, Joseph R Podojil, Benjamin L Clayton, Anita Zaremba, Tassie L Collins, Rejani B Kunjamma, Andrew P Robinson, Pedro Brugarolas, Robert H. Miller, Stephen D Miller, Brian Popko
Anatomy and Regenerative Biology Faculty Publications
Oligodendrocyte death contributes to the pathogenesis of the inflammatory demyelinating disease multiple sclerosis (MS). Nevertheless, current MS therapies are mainly immunomodulatory and have demonstrated limited ability to inhibit MS progression. Protection of oligodendrocytes is therefore a desirable strategy for alleviating disease. Here we demonstrate that enhancement of the integrated stress response using the FDA-approved drug guanabenz increases oligodendrocyte survival in culture and prevents hypomyelination in cerebellar explants in the presence of interferon-γ, a pro-inflammatory cytokine implicated in MS pathogenesis. In vivo, guanabenz treatment protects against oligodendrocyte loss caused by CNS-specific expression of interferon-γ. In a mouse model of MS, experimental …